| Graphite Bio is a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases. Co.'s primary product candidate GPH101 is an approach with the potential to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression. Co.'s pipeline also includes GPH102 for beta-thalassemia and GPH201 for X-linked severe combined immunodeficiency syndrome; GPH301 for Gaucher disease and an early-stage research program for alpha-1 antitrypsin deficiency; and various undisclosed programs in both hematopoietic stem cells and other cell types. We show 5 historical shares outstanding datapoints in our coverage of GRPH's shares outstanding history.|
Understanding the changing numbers of GRPH shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like GRPH versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching GRPH by allowing them to research GRPH shares outstanding history
as well as any other stock in our coverage universe.